Demographic and clinical characteristics of the patients at study entry.

<p>Demographic and clinical characteristics of the patients at study entry.</p

Adverse events during the planned 24-month follow-up period.

<p>Adverse events during the planned 24-month follow-up period.</p

Subgroup analysis of the Kaplan-Meier estimate of the time from remission to first relapse or death (during the planned 24 month-follow-up) in the cyclophosphamide (CYC) and methotrexate (MTX) groups.

<p>The <i>upper panel</i> shows the analysis in patients with GPA or MPA (granulomatosis with polyangiitis or microscopic polyangiitis) while the <i>lower panel</i> shows the analysis in patients with EGPA (eosinophilic granulomatosis with polyangiitis).</p

Relapse frequencies during the planned 24-month follow-up period.

<p>Relapse frequencies during the planned 24-month follow-up period.</p

DataSheet_1_COVID-19 outcomes in patients with a history of immune-mediated glomerular diseases.pdf

IntroductionPatients with immune-mediated glomerular diseases are considered at high risk for severe COVID-19 outcomes. However, conclusive evidence for this patient population is scarce.MethodsWe created a global registry and retrospectively collected clinical data of patients with COVID-19 and a previously diagnosed immune-mediated glomerular disease to characterize specific risk factors for severe COVID-19 outcomes.ResultsFifty-nine patients with a history of immune-mediated glomerular diseases were diagnosed with COVID-19 between 01.03.2020 and 31.08.2021. Over a mean follow-up period of 24.79 ± 18.89 days, ten patients (16.9%) developed acute kidney injury. Overall, 44.1% of patients were managed in an outpatient setting and therefore considered as having “non-severe” COVID-19, while 55.9% of patients had severe COVID-19 requiring hospitalization including worse outcomes. Comparing both groups, patients with severe COVID-19 were significantly older (53.55 ± 17.91 versus 39.77 ± 14.95 years, p = .003), had lower serum albumin levels at presentation (3.00 ± 0.80 g/dL versus 3.99 ± 0.68 g/dL, p = .016) and had a higher risk of developing acute kidney injury (27% versus 4%, p = .018). Male sex (p ConclusionOlder age, male sex, ongoing intake of corticosteroids and lower serum albumin levels at presentation were identified as risk factors for severe COVID-19 outcomes in patients with a history of various immune-mediated glomerular diseases.</p